Gilead Sciences (GILD)

66.20 -0.32 (0.48%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/24/19 *Est.)
- M&A (12/31/17 *Est)
- Conference (6/5/2019)

Latest Headlines

Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 May 21, 2019 4:01 PM - BizWire Gilead Sciences (GILD) PT Raised to $79 at SVB Leerink May 21, 2019 7:32 AM - StreetInsider Credit Suisse Starts Gilead Sciences (GILD) at Neutral May 20, 2019 4:28 PM - StreetInsider Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019 May 15, 2019 5:00 PM - BizWire Form 4 GILEAD SCIENCES INC For: May 08 Filed by: Hamill Laura May 10, 2019 6:55 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: BARTON JACQUELINE K May 10, 2019 5:41 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: Cogan John Francis May 10, 2019 5:37 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: Kramer Kelly A. May 10, 2019 5:34 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: Lofton Kevin E May 10, 2019 5:32 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: MANWANI HARISH May 10, 2019 5:28 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: Whitley Richard James May 10, 2019 5:25 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: WILSON GAYLE E May 10, 2019 5:21 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 08 Filed by: WOLD OLSEN PER May 10, 2019 5:19 PM - SEC Filing Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic May 9, 2019 5:11 PM - BizWire Form 8-K GILEAD SCIENCES INC For: May 08 May 9, 2019 4:35 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 07 Filed by: WOLD OLSEN PER May 8, 2019 6:53 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 07 Filed by: MANWANI HARISH May 8, 2019 6:45 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 07 Filed by: Whitley Richard James May 8, 2019 6:43 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 07 Filed by: WILSON GAYLE E May 8, 2019 6:40 PM - SEC Filing Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease May 8, 2019 7:00 AM - BizWire Form 10-Q GILEAD SCIENCES INC For: Mar 31 May 8, 2019 6:34 AM - SEC Filing Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14 May 6, 2019 4:01 PM - BizWire Gilead Sciences (GILD) PT Raised to $83 at Morgan Stanley May 3, 2019 8:32 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $83 at Raymond James May 3, 2019 7:47 AM - StreetInsider Gilead Sciences (GILD) PT Raised to $91 at RBC Capital May 3, 2019 6:28 AM - StreetInsider Options expected to have increasing volume: MNST SHAK GILD LOCO X May 3, 2019 4:18 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: May 01 Filed by: Whitley Richard James May 2, 2019 6:49 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: May 01 Filed by: Cogan John Francis May 2, 2019 6:46 PM - SEC Filing Gilead Sciences (GILD) Declares $0.63 Quarterly Dividend; 3.9% Yield May 2, 2019 5:22 PM - StreetInsider Form 8-K GILEAD SCIENCES INC For: May 02 May 2, 2019 4:07 PM - SEC Filing Gilead Sciences (GILD) Tops Q1 EPS by 15c, Reiterate Guidance May 2, 2019 4:02 PM - StreetInsider Gilead Sciences Announces Second Quarter 2019 Dividend May 2, 2019 4:02 PM - BizWire Gilead Sciences Announces First Quarter 2019 Financial Results May 2, 2019 4:01 PM - BizWire Gilead Sciences (GILD) option implied volatility elevated into EPS and outlook May 2, 2019 11:10 AM - StreetInsider Gilead Sciences (GILD) option implied volatility elevated into EPS and growth outlook May 2, 2019 5:35 AM - StreetInsider Form 8-K GILEAD SCIENCES INC For: Apr 30 May 1, 2019 3:14 PM - SEC Filing Gilead Sciences (GILD) May weekly option implied volatility above 60 into EPS May 1, 2019 10:53 AM - StreetInsider Gilead Sciences (GILD) option implied volatility elevated into EPS and outlook May 1, 2019 5:19 AM - StreetInsider Gilead Sciences (GILD) CFO Robin Washington to Step Down in Early 2020 April 30, 2019 4:27 PM - StreetInsider Gilead Sciences’ Chief Financial Officer Robin Washington to Step Down in Early 2020 April 30, 2019 4:27 PM - BizWire Bernstein Starts Gilead Sciences (GILD) at Outperform April 26, 2019 6:21 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Apr 24 Filed by: Lofton Kevin E April 25, 2019 6:52 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Apr 24 Filed by: Cogan John Francis April 25, 2019 6:49 PM - SEC Filing Gilead Sciences (GILD) Reports Topline Data from Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) April 25, 2019 8:01 AM - StreetInsider Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) April 25, 2019 8:00 AM - BizWire Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities April 24, 2019 8:30 AM - BizWire U.S. Proposes Increased Payments for Car-T Cancer Treatments - Bloomberg April 23, 2019 4:23 PM - StreetInsider Gilead Sciences (GILD) KOL Call Takeaways - Oppenheimer April 23, 2019 9:26 AM - StreetInsider Gilead Sciences (GILD) PT Raised to $86 at Raymond James April 23, 2019 7:28 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Apr 17 Filed by: Cogan John Francis April 18, 2019 7:05 PM - SEC Filing Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019 April 18, 2019 4:05 PM - BizWire Form 10-K/A GILEAD SCIENCES INC For: Dec 31 April 18, 2019 6:05 AM - SEC Filing Gilead Sciences (GILD) option implied volatility as shares trade near six-year lows April 16, 2019 10:18 AM - StreetInsider Gilead Sciences (GILD), insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for NASH April 16, 2019 7:01 AM - StreetInsider Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis April 16, 2019 7:00 AM - BizWire Form 4 GILEAD SCIENCES INC For: Apr 10 Filed by: Cogan John Francis April 12, 2019 6:29 PM - SEC Filing Gilead Sciences (GILD), Novo Nordisk (NVO) Announce Intent to Initiate a Clinical Collaboration in NASH April 12, 2019 6:31 AM - StreetInsider Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH April 12, 2019 4:00 AM - BizWire Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019 April 11, 2019 9:18 AM - BizWire Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019 April 11, 2019 2:00 AM - BizWire Gilead Sciences (GILD) to layoff one-fifth of sales force - STAT April 10, 2019 3:43 PM - StreetInsider UBS Upgrades Gilead Sciences (GILD) to Buy; 'Turning the Corner' April 10, 2019 6:11 AM - StreetInsider Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases April 9, 2019 12:00 PM - BizWire Gilead Sciences (GILD) ticks slightly lower after FDA approves first two-drug complete regimen for HIV-infected patients April 8, 2019 3:37 PM - StreetInsider Gilead Sciences (GILD) Submits sNDA to FDA for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis April 5, 2019 8:31 AM - StreetInsider Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis April 5, 2019 8:30 AM - BizWire Form 4 GILEAD SCIENCES INC For: Apr 03 Filed by: Cogan John Francis April 4, 2019 7:32 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Apr 01 Filed by: Whitley Richard James April 2, 2019 8:11 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Mar 28 Filed by: Lofton Kevin E April 1, 2019 7:20 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Mar 28 Filed by: Whitley Richard James April 1, 2019 7:17 PM - SEC Filing Gilead Sciences (GILD) FINCH 1&3 Trials Indicate Similar Efficacy To AbbVie (ABBV) - Baird March 29, 2019 7:53 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Mar 27 Filed by: Cogan John Francis March 28, 2019 6:10 PM - SEC Filing GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) March 28, 2019 5:24 PM - StreetInsider GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) March 28, 2019 5:23 PM - StreetInsider GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) March 28, 2019 5:09 PM - StreetInsider GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) March 28, 2019 5:08 PM - StreetInsider Galapagos NV (GLPG), Gilead (GILD) Report Filgotinib Meets Primary & Secondary Endpoints in Phase 3 Finch 1 Rheumatoid Arthritis Study March 28, 2019 5:04 PM - StreetInsider Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients March 28, 2019 5:04 PM - BizWire Gilead Sciences (GILD), Galapagos (GLPG) Report Updated Safety Information for Filgotinib in RA March 28, 2019 5:03 PM - StreetInsider Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study March 28, 2019 5:03 PM - BizWire GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS March 28, 2019 5:03 PM - StreetInsider Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA) March 28, 2019 5:02 PM - BizWire GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY March 28, 2019 5:02 PM - StreetInsider GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS March 28, 2019 5:02 PM - StreetInsider GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY March 28, 2019 5:01 PM - StreetInsider Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia March 28, 2019 5:00 AM - BizWire Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019 March 27, 2019 6:06 AM - BizWire Gilead (GILD) Announces Japan's MHLW Approved its Biktarvy for Treatment of HIV-1 Infection March 26, 2019 8:32 AM - StreetInsider Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection March 26, 2019 8:30 AM - BizWire Form DEFA14A GILEAD SCIENCES INC March 25, 2019 4:07 PM - SEC Filing Form DEF 14A GILEAD SCIENCES INC For: May 08 March 25, 2019 4:07 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Mar 20 Filed by: Cogan John Francis March 21, 2019 7:09 PM - SEC Filing Gilead Sciences (GILD) Benefit/Risk Profile Improves - Oppenheimer March 19, 2019 9:39 AM - StreetInsider Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results March 18, 2019 7:30 AM - BizWire Form PRE 14A GILEAD SCIENCES INC For: May 08 March 15, 2019 4:23 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Feb 12 Filed by: Washington Robin L March 14, 2019 4:49 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Feb 15 Filed by: Pletcher Brett A March 14, 2019 4:33 PM - SEC Filing BMO Capital Starts Gilead Sciences (GILD) at Outperform March 14, 2019 4:11 PM - StreetInsider Agenus (AGEN) Secures $7.5M Milestone Payment from Gilead Sciences, Inc. (GILD) March 13, 2019 8:34 AM - StreetInsider Gilead Sciences (GILD) Announces Data From Two Studies Supporting Further Development of GS-6207 March 7, 2019 5:31 PM - StreetInsider Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies March 7, 2019 5:30 PM - BizWire Gilead (GILD) Presents Data on Biktarvy in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance March 6, 2019 5:31 PM - StreetInsider Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women March 6, 2019 5:30 PM - BizWire Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance March 6, 2019 5:30 PM - BizWire Gilead Sciences (GILD) DISCOVER HIV Trial Meets Primary and Secondary Endpoints March 6, 2019 2:12 PM - StreetInsider Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection March 6, 2019 2:10 PM - BizWire Gilead Sciences (GILD) Exec Turnover Is Understandable, Jefferies Reits Buy March 6, 2019 9:08 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Feb 15 Filed by: Alton Gregg H March 5, 2019 7:49 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Mar 01 Filed by: O'Day Daniel Patrick March 5, 2019 7:41 PM - SEC Filing Gilead Sciences (GILD) EVP of Oncology Therapeutics, Alessandro Riva, to Leave March 5, 2019 4:31 PM - StreetInsider Gilead Announces Senior Management Change March 5, 2019 4:30 PM - BizWire Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12 March 5, 2019 4:05 PM - BizWire Form 3 GILEAD SCIENCES INC For: Feb 26 Filed by: O'Day Daniel Patrick March 1, 2019 5:12 PM - SEC Filing Form 8-K GILEAD SCIENCES INC For: Mar 01 March 1, 2019 10:16 AM - SEC Filing Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV February 26, 2019 4:30 PM - BizWire Form 10-K GILEAD SCIENCES INC For: Dec 31 February 26, 2019 6:07 AM - SEC Filing Form CT ORDER GILEAD SCIENCES INC February 21, 2019 11:50 AM - SEC Filing Full Article List